Cytometric Therapeutics is advancing a new era of precision oncology by combining live-cell functional testing with translational research. Our mission is to develop therapies that target disease while respecting the individuality of each patient’s biology. We believe precision medicine should unite scientific accuracy with compassion and measurable results.
Cytometric Therapeutics grew from decades of research focused on one central question:
How can we directly measure how a patient’s tumor responds to treatment before treatment begins?
That question inspired the development of a laboratory method that tests living tumor cells against a broad range of drugs. Rather than predicting outcomes, this process observes how real tumor cells behave under controlled treatment conditions.
This approach evolved into the SynRx™ platform, a system that identifies the most effective therapies with precision and lower toxicity potential. Today, Cytometric Therapeutics brings together functional data, translational research, and clinical development to bridge the gap between discovery and patient care.
Cytometric Therapeutics applies SynRx™ to discover, validate, and advance new therapeutic candidates. By integrating laboratory data, computational analysis, and clinical readiness, we are defining a new model of cancer research where results are seen, measured, and acted upon.
With its first clinical program advancing toward human studies, Cytometric Therapeutics continues to expand its research capabilities and partnerships in oncology and drug discovery. Our teams in New York and California share a single goal: to translate functional precision into therapies that improve outcomes for patients facing the most difficult cancers.
Cytometric Therapeutics is built on curiosity, integrity, and shared discovery. We seek individuals who value collaboration and believe that rigorous science and compassion belong in the same room.
Behind every advancement is a group of researchers and leaders committed to translating precision into progress. Our leadership combines decades of experience in oncology, cytometry, and translational medicine — guiding a culture where ideas move freely from the lab to the clinic.